Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04487301 · ClinicalTrials.gov registry record

A Cross-Sectional Study to Assess Walking Performance in Subjects With Peripheral Artery and End Stage Kidney Disease

A clinical trial of Peripheral Artery Disease and End Stage Renal Disease on Dialysis, sponsored by Sanifit Therapeutics S. A..

Completed
Registry status
36
Enrollment target
7
Study locations

NCT04487301 is a study of Peripheral Artery Disease and End Stage Renal Disease on Dialysis that has completed, run by Sanifit Therapeutics S. A.. The registered enrollment target is 36 participants, below the 126-participant average among 50 other Peripheral Artery Disease trials with a reported enrollment target (71% lower). The trial reports 7 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04487301, a study of Peripheral Artery Disease and End Stage Renal Disease on Dialysis, has completed, sponsored by Sanifit Therapeutics S. A..

COMPLETED
Registry status
36 participants
Enrollment target
7
Study locations

Study Summary

A cross-sectional, non-interventional study to assess walking performance, vascular function, and lower limb calcification in subjects with peripheral artery disease and end-stage kidney disease (PAD-ESKD) receiving hemodialysis.

Study Locations (7)

Massachusetts

  • Brigham and Women's Hospital - Boston
  • Boston Medical Center - Boston

California

  • Valley Renal Medical Group - Northridge

Florida

  • Horizon Medical Research - Coral Gables

Missouri

  • St Louis Kidney Care - St Louis

North Carolina

  • Mountain Kidney & Hypertension Associates - Asheville

Texas

  • Houston Medical Research - Houston

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2020-11-16
Est. Completion 2021-06-12

Sponsor

Sanifit Therapeutics S. A.

4 total trials

What the Registry Record Tells You About NCT04487301

The ClinicalTrials.gov registry entry for NCT04487301 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 126-participant average among 50 other Peripheral Artery Disease trials with a reported enrollment target (71% lower). The listed sponsor is Sanifit Therapeutics S. A., which has 4 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Peripheral Artery Disease appearing as the primary indexed condition, and to 0 interventions.

NCT04487301 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Massachusetts, California, Florida.

Frequently Asked Questions

What is clinical trial NCT04487301 about?

NCT04487301 is a clinical study titled "A Cross-Sectional Study to Assess Walking Performance in Subjects With Peripheral Artery and End Stage Kidney Disease". A cross-sectional, non-interventional study to assess walking performance, vascular function, and lower limb calcification in subjects with peripheral artery disease and end-stage kidney disease (PAD-ESKD) receiving hemodialysis.

What is the current status of trial NCT04487301?

This trial is currently completed. The enrollment target is 36 participants. The study started on 2020-11-16. Estimated completion is 2021-06-12.

What conditions does trial NCT04487301 study?

This clinical trial studies the following conditions: Peripheral Artery Disease, End Stage Renal Disease on Dialysis.

Who is sponsoring clinical trial NCT04487301?

This trial is sponsored by Sanifit Therapeutics S. A., which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04487301 being conducted?

This trial has 7 study locations across California, Florida, Massachusetts, Missouri, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Peripheral Artery Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.